Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Orange County Retina Medical Group is a leading retina specialty practice established in 1979. It offers advanced diagnostics, therapeutics—including intravitreal injections of anti–VEGF agents like aflibercept ("Eylea"), ranibizumab ("Lucentis"), bevacizumab ("Avastin")—and surgical interventions for complex retinal diseases. The group also conducts clinical trials for new treatments targeting conditions such as wet age-related macular degeneration, diabetic macular edema, retinal vein occlusions, cataract prevention, uveitis, and bacterial conjunctivitis.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Orange County Retina Medical Group.